Meeting
2024 ASCO Gastrointestinal Cancers Symposium
Fruquintinib with PD-1 inhibitors versus fruquintinib monotherapy in late-line mCRC: A retrospective cohort study based on propensity score matching.
Authors
Tianqi An
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Tianqi An , Yugui Lian , Quanbo Zhou , Chao Zhao , Zheng Wang , Ruihua Zhao
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 139)
DOI
10.1200/JCO.2024.42.3_suppl.139
Abstract #
139
Poster Bd #
J5
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Fruquintinib with PD-1 inhibitors versus TAS-102 with bevacizumab in late-line mCRC: A retrospective cohort study based on propensity score matching.
First Author: Rongrong Li
Poster
2012 Gastrointestinal Cancers Symposium
Efficacy of vemurafenib (V) a selective V600EBRAF inhibitor, as monotherapy or in combination with erlotinib (Erl) or erbitux (Erb) and irinotecan (Iri) doublets and triplets in a colorectal cancer (CRC) xenograft model.
First Author: Brian Higgins
Poster
2024 ASCO Gastrointestinal Cancers Symposium
First report of the randomized phase III study of bi-weekly trifluridine/tipiracil (FTD/TPI) plus bevacizumab (BEV) vs. FTD/TPI monotherapy for chemorefractory metastatic colorectal cancer (mCRC): JCOG2014 (ROBiTS).
First Author: Hironaga Satake
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Effect of fruquintinib on programmed death receptor-1 blockade antitumor immune responses in colorectal cancer.
First Author: Qingli Li